1. Home
  2. ENTO vs STAF Comparison

ENTO vs STAF Comparison

Compare ENTO & STAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTO
  • STAF
  • Stock Information
  • Founded
  • ENTO 2014
  • STAF 2009
  • Country
  • ENTO United States
  • STAF United States
  • Employees
  • ENTO N/A
  • STAF N/A
  • Industry
  • ENTO Biotechnology: Pharmaceutical Preparations
  • STAF Professional Services
  • Sector
  • ENTO Health Care
  • STAF Consumer Discretionary
  • Exchange
  • ENTO Nasdaq
  • STAF Nasdaq
  • Market Cap
  • ENTO 1.2M
  • STAF 1.2M
  • IPO Year
  • ENTO 2016
  • STAF N/A
  • Fundamental
  • Price
  • ENTO $0.62
  • STAF $2.00
  • Analyst Decision
  • ENTO
  • STAF
  • Analyst Count
  • ENTO 0
  • STAF 0
  • Target Price
  • ENTO N/A
  • STAF N/A
  • AVG Volume (30 Days)
  • ENTO 924.5K
  • STAF 3.0M
  • Earning Date
  • ENTO 10-21-2024
  • STAF 08-12-2024
  • Dividend Yield
  • ENTO N/A
  • STAF N/A
  • EPS Growth
  • ENTO N/A
  • STAF N/A
  • EPS
  • ENTO N/A
  • STAF N/A
  • Revenue
  • ENTO N/A
  • STAF $180,258,000.00
  • Revenue This Year
  • ENTO N/A
  • STAF $1.94
  • Revenue Next Year
  • ENTO N/A
  • STAF $8.38
  • P/E Ratio
  • ENTO N/A
  • STAF N/A
  • Revenue Growth
  • ENTO N/A
  • STAF 4.69
  • 52 Week Low
  • ENTO $0.19
  • STAF $1.08
  • 52 Week High
  • ENTO $14.51
  • STAF $6.70
  • Technical
  • Relative Strength Index (RSI)
  • ENTO 59.35
  • STAF 59.18
  • Support Level
  • ENTO $0.38
  • STAF $1.93
  • Resistance Level
  • ENTO $0.87
  • STAF $5.69
  • Average True Range (ATR)
  • ENTO 0.14
  • STAF 0.45
  • MACD
  • ENTO 0.03
  • STAF 0.12
  • Stochastic Oscillator
  • ENTO 52.57
  • STAF 17.82

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

About STAF Staffing 360 Solutions Inc. (DE)

Staffing 360 Solutions Inc operates in the international staffing sector. It is engaged in the execution of an international buy-integrate-build process through the acquisition of domestic and international staffing organizations. The company operates through three Business Streams: Professional Staffing, Commercial Staffing, and Employer of Record. It primarily supports accounting and finance, information technology, engineering, administration, and commercial disciplines.

Share on Social Networks: